Clinical Trial Update: HLA-B*5801 Screening to Prevent Allopurinol-induced Severe Cutaneous Adverse Reaction [NA]

View source ↗

Summary

A clinical trial update describes using HLA-B*5801 screening to prevent allopurinol-induced Stevens-Johnson Syndrome, particularly in patients with chronic kidn…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Stevens-johnson Syndrome

Drugs mentioned

• Allopurinol (Allopurinol)

Snippet

Sponsor: Seoul National University Hospital | Conditions: Stevens-Johnson Syndrome, Kidney Failure, Chronic | NA | Status: UNKNOWN